Ann: Updated COVID-19 RAT receives Regulatory Approval in Europe, page-135

Highlights for the Q3 FY22 Quarter Include:
• Technology transfer for manufacturing Combo SARSCoV-2 Influenza A/B Ag Rapid Diagnostic Test (RDT)
with Operon has commenced.
• Australian clinical trial progresses as planned.
• Contracted Clinical Research Organisation (CRO) in
Spain to conduct prospective clinical trials for COVID19 RAT - to support TGA and EU Common List
registrations
• Distributor stocking and customer orders for EuGeni
Readers and Covid-19 RATs in Europe.
• Continued technical progress with collaborators with
results demonstrating that AnteoX binder formulation
improved the test battery's cycle life by up to 100% at
70% capacity retention.
• AnteoX increased anode tensile strength by up to
56%, helping to manage the volume expansion of
silicon-containing anodes, thereby improving battery
electrochemical performance and longevity

yes, ..... and also the battery milestones in this ANN:ASX is what Merc and Ford have been touting in their latest EV promotions.
as already discussed significant news is due.